Enanta Pharmaceuticals Inc (ENTA)

[willyw]

I don't think there was; not in my mind.
I think it was general market skittishness and Fed rate hike fears.
I also think they are trying to shake off a few more weak hands before the stock continues upward.

I am expecting very good news at AASLD. All the places I watch seem positive.
1) They have already mentioned the dosage for G-1 yielded 12 week 100% cure rates. Even Harvoni didn't hit 100% and they achieved 8 weeks for some groups. 530 and 493 could possibly hit it for a larger sub group population. (ie; better than Harvoni)

2) A genotype 3 cure rate will only have to be 12 weeks, and may remain so for some time. They may be comparable to what Gilead has to offer. Equal or better to Harvoni. Comparable to GILD next gen? (we will see clues at AASLD)

3) Per RAV's this looks like it could be effective, where some competitors treatments are not. Could be a new area of strength or superiority?

4) It could be that the strength of the 2nd gen program may either keep existing PBM agreements and or attract new ones. It could be tough for Merck unless they have a good nuke program; likewise JNJ.

Seems as though the market has lost some fear and ENTA may be recovering. Chart looks OK and fundamentals seem promising.